Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy?

Samantha Brunt, L.A. Cysique, S. Lee, Sally Burrows, B.J. Brew, Patricia Price

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    © Mary Ann Liebert, Inc. 2016.HIV+ persons stable on antiretroviral therapy (ART) face early onset of age-related diseases. This may arise from a high burden of cytomegalovirus (CMV). To address the role of CMV, we investigated univariate and multivariate associations between markers of systemic and endothelial inflammation, vascular damage, insulin resistance (IR), neurocognitive decline, and antibodies reactive with CMV. In this study, HIV+ participants (n = 91) aged >45 years with 2 years on ART were assessed for cardiovascular risk (the D:A:D algorithm), type II diabetes (the HOMA-IR index), and neurocognitive performance. Blood samples were assayed for lipids, T cells, insulin, glucose, C-reactive protein, CX3CL1, sTNF-R1, total immunoglobulin G (IgG), and antibodies reactive with CMV lysate, glycoprotein B, or immediate-early-1. Levels of antibodies detected with the three antigens were tightly correlated. Levels of CMV lysate antibody were higher in patients than in age-matched healthy controls and reflected their nadir CD4 T-cell count (p = .001), total IgG (p = .02), and age (p = .08). Levels of CMV lysate antibody correlated with D:A:D score (p = .04), neurocognitive performance (p = .045), and fasting insulin (p = .02). In multivariable analyses, some associations reflected the effect of age, but CMV lysate antibody and CD8 T-cell counts were significant predictors of the HOMA-IR index (R2 = 0.09, p = .01) independent of age. We conclude that associations between levels of CMV antibodies, cardiovascular risk, and neurocognitive health in HIV+ patients stable on ART are moderated by age-associated increases in response to CMV, while CMV antibodies may be independently linked with IR.
    Original languageEnglish
    Pages (from-to)567-572
    JournalAIDS Research and Human Retroviruses
    Volume32
    Issue number6
    Early online date16 Mar 2016
    DOIs
    Publication statusPublished - 24 May 2016

    Fingerprint

    Cytomegalovirus
    Communication
    HIV
    Antibodies
    Insulin Resistance
    Therapeutics
    T-Lymphocytes
    Immunoglobulin G
    Insulin
    CD4 Lymphocyte Count
    Age of Onset
    C-Reactive Protein
    Type 2 Diabetes Mellitus
    Blood Vessels
    Fasting
    Cell Count
    Inflammation
    Lipids
    Antigens
    Glucose

    Cite this

    @article{cdc8e5f163b2487ea65635a5dd955936,
    title = "Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy?",
    abstract = "{\circledC} Mary Ann Liebert, Inc. 2016.HIV+ persons stable on antiretroviral therapy (ART) face early onset of age-related diseases. This may arise from a high burden of cytomegalovirus (CMV). To address the role of CMV, we investigated univariate and multivariate associations between markers of systemic and endothelial inflammation, vascular damage, insulin resistance (IR), neurocognitive decline, and antibodies reactive with CMV. In this study, HIV+ participants (n = 91) aged >45 years with 2 years on ART were assessed for cardiovascular risk (the D:A:D algorithm), type II diabetes (the HOMA-IR index), and neurocognitive performance. Blood samples were assayed for lipids, T cells, insulin, glucose, C-reactive protein, CX3CL1, sTNF-R1, total immunoglobulin G (IgG), and antibodies reactive with CMV lysate, glycoprotein B, or immediate-early-1. Levels of antibodies detected with the three antigens were tightly correlated. Levels of CMV lysate antibody were higher in patients than in age-matched healthy controls and reflected their nadir CD4 T-cell count (p = .001), total IgG (p = .02), and age (p = .08). Levels of CMV lysate antibody correlated with D:A:D score (p = .04), neurocognitive performance (p = .045), and fasting insulin (p = .02). In multivariable analyses, some associations reflected the effect of age, but CMV lysate antibody and CD8 T-cell counts were significant predictors of the HOMA-IR index (R2 = 0.09, p = .01) independent of age. We conclude that associations between levels of CMV antibodies, cardiovascular risk, and neurocognitive health in HIV+ patients stable on ART are moderated by age-associated increases in response to CMV, while CMV antibodies may be independently linked with IR.",
    author = "Samantha Brunt and L.A. Cysique and S. Lee and Sally Burrows and B.J. Brew and Patricia Price",
    year = "2016",
    month = "5",
    day = "24",
    doi = "10.1089/aid.2015.0328",
    language = "English",
    volume = "32",
    pages = "567--572",
    journal = "AIDS Research and Human Retroviruses",
    issn = "0889-2229",
    publisher = "Mary Ann Liebert Inc",
    number = "6",

    }

    Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy? / Brunt, Samantha; Cysique, L.A.; Lee, S.; Burrows, Sally; Brew, B.J.; Price, Patricia.

    In: AIDS Research and Human Retroviruses, Vol. 32, No. 6, 24.05.2016, p. 567-572.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy?

    AU - Brunt, Samantha

    AU - Cysique, L.A.

    AU - Lee, S.

    AU - Burrows, Sally

    AU - Brew, B.J.

    AU - Price, Patricia

    PY - 2016/5/24

    Y1 - 2016/5/24

    N2 - © Mary Ann Liebert, Inc. 2016.HIV+ persons stable on antiretroviral therapy (ART) face early onset of age-related diseases. This may arise from a high burden of cytomegalovirus (CMV). To address the role of CMV, we investigated univariate and multivariate associations between markers of systemic and endothelial inflammation, vascular damage, insulin resistance (IR), neurocognitive decline, and antibodies reactive with CMV. In this study, HIV+ participants (n = 91) aged >45 years with 2 years on ART were assessed for cardiovascular risk (the D:A:D algorithm), type II diabetes (the HOMA-IR index), and neurocognitive performance. Blood samples were assayed for lipids, T cells, insulin, glucose, C-reactive protein, CX3CL1, sTNF-R1, total immunoglobulin G (IgG), and antibodies reactive with CMV lysate, glycoprotein B, or immediate-early-1. Levels of antibodies detected with the three antigens were tightly correlated. Levels of CMV lysate antibody were higher in patients than in age-matched healthy controls and reflected their nadir CD4 T-cell count (p = .001), total IgG (p = .02), and age (p = .08). Levels of CMV lysate antibody correlated with D:A:D score (p = .04), neurocognitive performance (p = .045), and fasting insulin (p = .02). In multivariable analyses, some associations reflected the effect of age, but CMV lysate antibody and CD8 T-cell counts were significant predictors of the HOMA-IR index (R2 = 0.09, p = .01) independent of age. We conclude that associations between levels of CMV antibodies, cardiovascular risk, and neurocognitive health in HIV+ patients stable on ART are moderated by age-associated increases in response to CMV, while CMV antibodies may be independently linked with IR.

    AB - © Mary Ann Liebert, Inc. 2016.HIV+ persons stable on antiretroviral therapy (ART) face early onset of age-related diseases. This may arise from a high burden of cytomegalovirus (CMV). To address the role of CMV, we investigated univariate and multivariate associations between markers of systemic and endothelial inflammation, vascular damage, insulin resistance (IR), neurocognitive decline, and antibodies reactive with CMV. In this study, HIV+ participants (n = 91) aged >45 years with 2 years on ART were assessed for cardiovascular risk (the D:A:D algorithm), type II diabetes (the HOMA-IR index), and neurocognitive performance. Blood samples were assayed for lipids, T cells, insulin, glucose, C-reactive protein, CX3CL1, sTNF-R1, total immunoglobulin G (IgG), and antibodies reactive with CMV lysate, glycoprotein B, or immediate-early-1. Levels of antibodies detected with the three antigens were tightly correlated. Levels of CMV lysate antibody were higher in patients than in age-matched healthy controls and reflected their nadir CD4 T-cell count (p = .001), total IgG (p = .02), and age (p = .08). Levels of CMV lysate antibody correlated with D:A:D score (p = .04), neurocognitive performance (p = .045), and fasting insulin (p = .02). In multivariable analyses, some associations reflected the effect of age, but CMV lysate antibody and CD8 T-cell counts were significant predictors of the HOMA-IR index (R2 = 0.09, p = .01) independent of age. We conclude that associations between levels of CMV antibodies, cardiovascular risk, and neurocognitive health in HIV+ patients stable on ART are moderated by age-associated increases in response to CMV, while CMV antibodies may be independently linked with IR.

    U2 - 10.1089/aid.2015.0328

    DO - 10.1089/aid.2015.0328

    M3 - Article

    VL - 32

    SP - 567

    EP - 572

    JO - AIDS Research and Human Retroviruses

    JF - AIDS Research and Human Retroviruses

    SN - 0889-2229

    IS - 6

    ER -